Back to Search
Start Over
Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits
- Source :
- BMC Immunology, BMC Immunology, Vol 20, Iss 1, Pp 1-12 (2019)
- Publication Year :
- 2017
-
Abstract
- Background In this study, seven adjuvants were compared for use with Plasmodium falciparum DiCo-Apical Membrane Antigen 1 (Pf-DiCo-AMA1), with the aim to identify an ideal adjuvant which yields high antibody titres and potentially broadens the responses in clinical trials. The following adjuvant formulations were evaluated: SE, SE-GLA, Liposomes, Liposomes-GLA, CoVaccine HT™, ImSaVac-P and ImSaVac-P o/w. The study was performed in rabbits, which were immunized with FVO-AMA1 in combination with one of the seven adjuvants. Antibody levels (humoral responses) and functional activity of the antibodies induced against malaria vaccine candidate AMA1 were evaluated. Thus, in this study the ideal adjuvant is expected to induce high functional antibody levels, a long-lived response, and a broad cross-strain activity. Results AMA1 formulated in all adjuvants was immunogenic. However, the magnitude of the immune responses differed between the seven adjuvants. The highest IgG levels were observed for the CoVaccine HT™ group, this was statistically significant for all four AMA1 variants versus all other adjuvant groups. No differences were observed in the breadth of the humoral response, i.e., increased recognition of AMA1 variants. Also, Growth Inhibition Activity (GIA) for both Plasmodium falciparum strains (FCR3 – homologous to FVO AMA1 protein and NF54 – heterologous to FVO AMA1 protein) were significantly higher in the CoVaccine HT™ group as compared to the other adjuvant groups. Conclusions In brief, all seven vaccine – adjuvant formulations were immunogenic. The magnitude of the immune responses differed between the seven adjuvants. No statistically significant differences were observed in the breadth of the humoral response, nor in longevity of the response. Nevertheless, AMA1 formulated in CoVaccine HT™ appeared as the best adjuvant for use in clinical trials. Electronic supplementary material The online version of this article (10.1186/s12865-019-0307-y) contains supplementary material, which is available to authorized users.
- Subjects :
- 0301 basic medicine
Allergy
medicine.medical_treatment
Protozoan Proteins
Antibodies, Protozoan
chemistry.chemical_compound
0302 clinical medicine
CoVaccine HT™
Malaria, Falciparum
Malaria vaccine
AMA1
Rabbits
Antibody
Growth inhibition
Liposomes-GLA
Adjuvant
Research Article
lcsh:Immunologic diseases. Allergy
Immunology
Plasmodium falciparum
Heterologous
Antigens, Protozoan
Biology
ImSaVac-P
complex mixtures
03 medical and health sciences
SE-GLA
Immune system
Adjuvants, Immunologic
parasitic diseases
Malaria Vaccines
medicine
Animals
Adjuvants
SE
Membrane Proteins
biology.organism_classification
medicine.disease
Disease Models, Animal
030104 developmental biology
chemistry
Immunoglobulin G
Antibody Formation
Liposomes
biology.protein
Immunization
lcsh:RC581-607
030215 immunology
Subjects
Details
- ISSN :
- 14712172
- Volume :
- 20
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMC immunology
- Accession number :
- edsair.doi.dedup.....fb25bf7281e537025b13adfaebb096e8